Global pharmaceutical manufacturer, Indivior, has extended its partnership with Siemens with a new agreement to help create an automated Active Pharmaceutical Ingredient (API) manufacturing facility at its UK base in Hull.
FTSE 250 and NASDAQ-listed Indivior, is a manufacturer of pioneering, life-transforming treatment for substance use disorders and other serious mental illnesses. The new, 1,731 sq ft facility will house three new reactors, filter driers and a powder transfer system to enable Indivior to optimise production of its API Buprenorphine Hydrochloride. The work is part of…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login